ReviewAnnals of surgical oncology2022
Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study.
Review in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Gustave Roussy Immune (GRIm) score as a novel prognostic biomarker for gastrointestinal cancers: a meta-analysis of sixteen studies.World journal of surgical oncology · 2026Pooled it
- Pooled it
- Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Prognostic significance of the Gustave Roussy immune (GRIm) score in cancer patients: a meta-analysis.Annals of medicine · 2023Pooled it
- Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials.Cancer research communications · 2026Article
- Construction of prognostic models for colorectal cancer based on the perioperative modified Gustave Roussy Immune Score and machine learning.Frontiers in immunology · 2026Article
- A combined immune-nutritional score as a prognostic indicator in neoadjuvant-treated esophageal squamous cell carcinoma.Frontiers in immunology · 2026Article
- Survival of patients with advanced hepatocellular carcinoma based on Gustave Roussy immune score and portal vein tumor thrombosis: a single-center, retrospective, non-randomized case-controlled study.Discover oncology · 2025Article
- The modified-Gustave Roussy immune score: assessing immune prognosis in advanced gastric cancer patients at baseline.Future oncology (London, England) · 2025Article
- Gustave Roussy immune score as an independent prognostic factor for treatment response and survival in advanced renal cell carcinoma treated with nivolumab in second-line and beyond.Frontiers in oncology · 2025Article
- Association between Gustave Roussy Immune Score and delay in discharge among children and adolescents with mycoplasma pneumoniae pneumonia: a retrospective cohort study.Frontiers in pediatrics · 2025Article
- Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study.Annals of surgical oncology · 2024Article
- ASO Author Reflections: The Gustave Roussy Immune Score May Be a Useful Biomarker for Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Gastric Cancer.Annals of surgical oncology · 2024Article
- The Gustave Roussy Immune score is a powerful biomarker for predicting therapeutic resistance to chemotherapy in gastric cancer patients.Cancer chemotherapy and pharmacology · 2024Article
- Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool.Journal of cancer research and clinical oncology · 2024Article
- Albumin-derived Neutrophil-to-Lymphocyte Ratio Score as a Marker of Nivolumab Treatment Sensitivity in Gastric Cancer: A Multicenter Study.In vivo (Athens, Greece)Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdentification of positive biomarkers for the effects of nivolumab on patients with advanced gastric cancer (AGC) is significant. The Gustave Roussy Immune Score (GRIm-s) is associated with therapeutic resistance of immune checkpoint inhibitors (ICIs) in other cancers. This multicenter, retrospective study was designed to analyze the association of GRIm-s with therapeutic sensitivity of nivolumab in patients with AGC.
methodsWe reviewed 58 patients with AGC treated with nivolumab from October 2017 to November 2018 at five participating institutions. We performed blood tests before the start of nivolumab and after administration of two courses. We evaluated the correlation between the best overall response and GRIm-s. Additionally, we focused on the changes in GRIm-s before the start of nivolumab and after administration of two courses.
resultsOf the 58 patients, 21 (36.2%) were classified into the disease control (DC) group and 37 (63.8%) into the progressive disease (PD) group. GRIm-s before nivolumab treatment did not correlate with the best therapeutic response (p = 0.086). However, GRIm-s after two courses of nivolumab showed that significantly more PD cases were in the high-risk group (p < 0.0001). After two courses of nivolumab, overall survival was significantly worse in the high-risk group (p < 0.0001). For progression-free survival, the high-risk group had a significantly worse prognosis both before (p = 0.04) and after two courses of nivolumab treatment (p < 0.0001).
conclusionsGRIm-s after two courses of nivolumab and its changes compared to pretreatment values proved beneficial in predicting nivolumab sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.